中山醫學大學機構典藏 CSMUIR:Item 310902500/23963
English  |  正體中文  |  简体中文  |  全文笔数/总笔数 : 17938/22957 (78%)
造访人次 : 7403123      在线人数 : 126
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜寻范围 查询小技巧：
  • 您可在西文检索词汇前后加上"双引号"，以获取较精准的检索结果
  • 若欲以作者姓名搜寻，建议至进阶搜寻限定作者字段，可获得较完整数据
    •  进阶搜寻


    jsp.display-item.identifier=請使用永久網址來引用或連結此文件: https://ir.csmu.edu.tw:8080/ir/handle/310902500/23963


    题名: Real-world experience of switching from tenofovir disoproxil fumarate to tenofovir alafenamide in patients with chronic hepatitis B: a retrospective study
    作者: Su, PY;Su, WW;Hsu, YC;Huang, SP;Yen, HH
    关键词: Tenofovir Disoproxil Fumarate;Tenofovir alafenamide;Chronic hepatitis B;Switch
    日期: 2021
    上传时间: 2022-08-05T09:45:39Z (UTC)
    出版者: PEERJ INC
    ISSN: 2167-8359
    摘要: Background: Tenofovir alafenamide (TAF) has good viral suppression efficacy and less adverse effect than tenofovir disoproxil fumarate (TDF). Real-world studies on the antiviral efficacy and safety of switching from TDF to TAF in patients with chronic hepatitis B (CHB) are limited. Methods: This retrospective study included 167 nucleos(t)ide analogue (NA)-naive patients with CHB. All the patients received TDF at least 12 months before switching and TAF at least 12 months after switching at a single medical center. The Friedman test with Dunn-Bonferroni post hoc tests and repeated-measures analysis of variance was used to analyze the effect of complete viral suppression, alanine aminotransferase (ALT) level normalization, renal function changes, body weight, and body mass index in the periods before and after switching. Results: The mean age and TDF treatment duration were 52 +/- 11 years and 2.8 years (interquartile range, 1.51-5.15 years), respectively. The complete viral suppression rate was similar between the time of switching and 48 weeks after switching to TAF (77.8% vs 76%, P = 1.000). The percentage of alanine aminotransferase (ALT) normalization increased from 26.3% at TDF start to 81.4% (P < 0.001) at time of switching and 89.2% at 48 weeks after switching to TAF (P = 0.428). The median estimated glomerular filtration rate decreased from 100.09 mL/min/1.73 m(2) at TDF start to 91.97 mL/min/1.73 m(2) (P < 0.001) at the time of switching and stabilized at 48 weeks after switching to TAF (93.47 mL/min/1.73m(2), P = 1.000). The body weight decreased from 69.2 +/- 12.2 kg at TDF start to 67.4 +/- 12.1 kg (P < 0.001) at the time of switching to TAF and returned to 68.7 +/- 12.7 kg (P < 0.001) 48 weeks thereafter. The body mass index (BMI) decreased from 25 +/- 3.3 kg/m(2) at TDF start to 24.5 +/- 3.3 kg/m(2) (P = 0.002) at the time of switching to TAF and returned to 25.1 +/- 3.6 kg/m(2) (P < 0.001) 48 weeks thereafter. Conclusions: Our study showed that switching to TAF from TDF had good antiviral effectiveness and stabilized renal function. The body weight and BMI decreased during TDF therapy and regained after switching to TAF.
    URI: http://dx.doi.org/10.7717/peerj.12527
    https://www.webofscience.com/wos/woscc/full-record/WOS:000723040100002
    https://ir.csmu.edu.tw:8080/handle/310902500/23963
    關聯: PEERJ ,2021,v9
    显示于类别:[中山醫學大學研究成果] 期刊論文

    文件中的档案:

    档案 描述 大小格式浏览次数
    index.html0KbHTML165检视/开启


    SFX Query

    在CSMUIR中所有的数据项都受到原著作权保护.

    TAIR相关文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回馈